|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Information
Pharmacokinetics
| Indication
& Dosage | Action
| Interaction
Adverse
Effect & Precautions |
Brands available in Market
Pharmacokinetics
Gliclazide belongs to the group of
intermediate acting hypoglycaemic agents. It is rapidly absorbed from
the GIT, and is metabolised in the liver. It appears in the blood within
1-2 hrs. It is extensively plasma protein bound ( more than 90%). Peak
level is achieved in 4-6 hrs. The plasma t 1/2 is 8-12 hrs and its
duration of action is 12 hrs.
Indication
& Dosage
Oral
NONINSULIN-DEPENDENT DIABETES MELLITUS: 40-80mg/day increasing upto
320mg/day in div doses before breakdfast and evening meal. Elderly,
renal or hepatic damage: Start with lower doses and increase with care.
Stimulates insulin secretion by pancreatic beta cells. In the long-term reduces hepatic gluconeogenesis, and increases insulin effects by acting at receptor or post-receptor sites. Inhibits platelet aggregation and increases fibrinolysis.
The hypoglycaemic effect of gliclazide is potentiated by Phenylbutazone, aspirin, clofibrate, sulphonamides, oral anticoagulants and MAO inhibitors. Rifampicin, barbiturates, alcohol, diuretics, diazoxide, glucocorticoids,estrogens and sympathomimietic drugs antagonise the hypoglycaemic action of gliclazide.
Adverse
Effect & Precaution
Skin rash, urticaria, blood
dyscrasias, hypoglycaemia.
Precaution is to be taken in hypoglycaemia and
stress. During metabolic stress insulin may be needed in addition.
Extreme care should be taken during transfer of drug therapy.
Pregnancy: Contraindicated.
Breast Feeding: Use with caution/
Man: Use with caution.
